Effects of Atomoxetine on Cognitive Function in Schizophrenia
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the effects of atomoxetine (Strattera™) on prefrontal
cognitive functioning in persons with schizophrenia. Secondarily, the effects of atomoxetine
on positive and negative symptoms and on cigarette smoking consumption in persons with
schizophrenia will be examined.
Phase:
Phase 2
Details
Lead Sponsor:
Yale University
Collaborator:
National Alliance for Research on Schizophrenia and Depression